| Revenues | — | — | — |
| Product sales | 28,610a | 26,934a | 26,982a |
| Royalty, contract and other revenues | 144a | 182a | 299a |
| Total revenues | 28,754a | 27,116a | 27,281a |
| Costs and expenses | — | — | — |
| Cost of goods sold | -6,251a | -6,498a | -5,657a |
| Research and development expenses | -5,907a | -5,718a | -4,977a |
| Acquired in-process research and development expenses | -4,663a | -1,155a | -944a |
| In-process research and development impairments | -4,180a | -50a | -2,700a |
| Selling, general and administrative expenses | -6,091a | -6,090a | -5,673a |
| Total costs and expenses | -27,092a | -19,511a | -19,951a |
| Operating income | 1,662a | 7,605a | 7,330a |
| Interest expense | -977a | -944a | -935a |
| Other (income) expense, net | -6a | -198a | 581a |
| Income before income taxes | 690a | 6,859a | 5,814a |
| Income tax expense | -211a | -1,247a | -1,248a |
| Net income | 480a | 5,613a | 4,566a |
| Net loss attributable to noncontrolling interest | 0a | -52a | -26a |
| Net income attributable to Gilead | 480a | 5,665a | 4,592a |